Bildkälla: Stockfoto

Cyxone: Negative Results in Rabeximod Covid-19 trial - Redeye

Redeye gives an initial take on the negative top-line data from Cyxone’s Rabeximod phase II study in Moderate Covid-19 patients.

Redeye gives an initial take on the negative top-line data from Cyxone’s Rabeximod phase II study in Moderate Covid-19 patients.
Börsvärldens nyhetsbrev
ANNONSER